220 related articles for article (PubMed ID: 29357797)
1. Characteristics of Insulin-degrading Enzyme in Alzheimer's Disease: A Meta-Analysis.
Zhang H; Liu D; Huang H; Zhao Y; Zhou H
Curr Alzheimer Res; 2018; 15(7):610-617. PubMed ID: 29357797
[TBL] [Abstract][Full Text] [Related]
2. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P
J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774
[TBL] [Abstract][Full Text] [Related]
3. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele.
Cook DG; Leverenz JB; McMillan PJ; Kulstad JJ; Ericksen S; Roth RA; Schellenberg GD; Jin LW; Kovacina KS; Craft S
Am J Pathol; 2003 Jan; 162(1):313-9. PubMed ID: 12507914
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Aβ by insulin degrading enzyme (IDE) in Alzheimer's disease.
Del Campo M; Stargardt A; Veerhuis R; Reits E; Teunissen CE
Neurosci Lett; 2015 Mar; 589():47-51. PubMed ID: 25597881
[TBL] [Abstract][Full Text] [Related]
5. Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues.
Kochkina EG; Plesneva SA; Vasilev DS; Zhuravin IA; Turner AJ; Nalivaeva NN
Biogerontology; 2015 Aug; 16(4):473-84. PubMed ID: 25792373
[TBL] [Abstract][Full Text] [Related]
6. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease.
Edland SD
J Mol Neurosci; 2004; 23(3):213-7. PubMed ID: 15181249
[TBL] [Abstract][Full Text] [Related]
7. Regulatory feedback cycle of the insulin-degrading enzyme and the amyloid precursor protein intracellular domain: Implications for Alzheimer's disease.
Lauer AA; Mett J; Janitschke D; Thiel A; Stahlmann CP; Bachmann CM; Ritzmann F; Schrul B; Müller UC; Stein R; Riemenschneider M; Grimm HS; Hartmann T; Grimm MOW
Aging Cell; 2020 Nov; 19(11):e13264. PubMed ID: 33128835
[TBL] [Abstract][Full Text] [Related]
8. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
Zhao L; Teter B; Morihara T; Lim GP; Ambegaokar SS; Ubeda OJ; Frautschy SA; Cole GM
J Neurosci; 2004 Dec; 24(49):11120-6. PubMed ID: 15590928
[TBL] [Abstract][Full Text] [Related]
9. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.
Wang S; Wang R; Chen L; Bennett DA; Dickson DW; Wang DS
J Neurochem; 2010 Oct; 115(1):47-57. PubMed ID: 20663017
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology.
Vepsäläinen S; Hiltunen M; Helisalmi S; Wang J; van Groen T; Tanila H; Soininen H
Neurosci Lett; 2008 Jun; 438(2):216-20. PubMed ID: 18455870
[TBL] [Abstract][Full Text] [Related]
11. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.
Zhao Z; Xiang Z; Haroutunian V; Buxbaum JD; Stetka B; Pasinetti GM
Neurobiol Aging; 2007 Jun; 28(6):824-30. PubMed ID: 16769157
[TBL] [Abstract][Full Text] [Related]
12. 17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention.
Zhao L; Yao J; Mao Z; Chen S; Wang Y; Brinton RD
Neurobiol Aging; 2011 Nov; 32(11):1949-63. PubMed ID: 20053478
[TBL] [Abstract][Full Text] [Related]
13. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Qiu WQ; Folstein MF
Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206
[TBL] [Abstract][Full Text] [Related]
14. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
[TBL] [Abstract][Full Text] [Related]
15. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Li H; Wu J; Zhu L; Sha L; Yang S; Wei J; Ji L; Tang X; Mao K; Cao L; Wei N; Xie W; Yang Z
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29222348
[TBL] [Abstract][Full Text] [Related]
16. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques.
Bernstein HG; Ansorge S; Riederer P; Reiser M; Frölich L; Bogerts B
Neurosci Lett; 1999 Mar; 263(2-3):161-4. PubMed ID: 10213160
[TBL] [Abstract][Full Text] [Related]
17. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.
Caccamo A; Oddo S; Sugarman MC; Akbari Y; LaFerla FM
Neurobiol Aging; 2005 May; 26(5):645-54. PubMed ID: 15708439
[TBL] [Abstract][Full Text] [Related]
18. Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models.
Stargardt A; Gillis J; Kamphuis W; Wiemhoefer A; Kooijman L; Raspe M; Benckhuijsen W; Drijfhout JW; Hol EM; Reits E
Aging Cell; 2013 Jun; 12(3):499-507. PubMed ID: 23534431
[TBL] [Abstract][Full Text] [Related]
19. Copper(I) and copper(II) inhibit Aβ peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease.
Grasso G; Pietropaolo A; Spoto G; Pappalardo G; Tundo GR; Ciaccio C; Coletta M; Rizzarelli E
Chemistry; 2011 Feb; 17(9):2752-62. PubMed ID: 21274957
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of expression and function of neprilysin in Alzheimer's disease.
Zhang H; Liu D; Wang Y; Huang H; Zhao Y; Zhou H
Neurosci Lett; 2017 Sep; 657():69-76. PubMed ID: 28778804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
